Praxis Precision Medicines, Inc. Stock News

BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for

Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively

BOSTON, May 10, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for

BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for

The consensus price target hints at a 144.7% upside potential for Praxis Precision Medicines (PRAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend i

Innovative design of ongoing Phase 3 clinical program expected to set precedent for future clinical trials in essential tremor Innovative design of ongoing Phase 3 clinical program expected to set pre

Praxis Precision Medicines (PRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies fo

Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.

Praxis Precision Medicines, Inc. results from the phase 3 Essential3 program, using ulixacaltamide for the treatment of patients with essential tremor, expected in the 2nd half of 2024. Company believ

In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with prio

Presentation will be held virtually on Tuesday, March 26, 2024 at 8:00 a.m. ET Praxis leadership will be joined by key opinion leader in epilepsy Dr. Daniel Friedman, Professor of Neurology at NYU Gro